MEDIA RELEASE

QT VASCULAR TO ESTABLISH DRUG-COATING DEVELOPMENT CENTRE IN SINGAPORE WITH SUPPORT FROM EDB

Highlights:

- **QT Vascular to establish a drug-coating development centre in Singapore with EDB support**
- **QT Vascular to develop Chocolate Touch™ from Singapore**
- **Potential of Chocolate Touch™ underpinned by growing drug-coated balloon market**

SINGAPORE, 3 August 2015 – QT Vascular Ltd., together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced the establishment of its drug coating development centre in Singapore, with the support of the Singapore Economic Development Board ("**EDB**"). The centre will help to boost the Group's R&D efforts in its Chocolate Touch™ drug-coated angioplasty balloon program.

"We are very pleased to establish our drug coating development centre for the development of these products that can help such a large number of patients who suffer from cardiovascular disease in Singapore. This demonstrates that Singapore's biomedical sciences ecosystem presents companies with key capabilities to innovate and commercialize products for the region and beyond," stated Dr Eitan Konstantino, PhD, Chief Executive Officer of QT Vascular. ***"We also appreciate EDB's support and look forward to our continued strong partnership with Singapore."***

"We welcome QT Vascular's decision to establish its drug coating development centre in Singapore to develop new ways to improve minimally-invasive treatments and patient outcomes. Singapore continues to provide a conducive environment to support medtech companies to innovate and commercialise novel medical technologies for the region and beyond," said Mr. Kevin Lai, Executive Director, Biomedical Sciences and Consumer Businesses, EDB.

Drug-coated balloons ("**DCB**") are creating a significant new market space. In Q4 2014, when C.R. Bard first launched its DCB in the United States, it reached approximately US$18 million in global sales, compared with an analyst's estimate of US$11 million(1). In Europe and the US, DCBs are rapidly becoming the standard of care for certain peripheral interventions as they provide robust long-term outcomes. With the addition of the proven drug, paclitaxel, to the low trauma Chocolate® platform, Chocolate Touch™ offers the potential to address one of the major limitations of current drug-coated balloons, which is acute trauma in the form of vessel dissections. The Group believes this would allow its Chocolate Touch™ to stand out from the competition. In the US, two DCBs by other companies had received FDA approvals in the recent months. This is a positive development for the market, as it creates greater awareness for DCBs and the Centers for Medicare and Medicaid Services also recently established supplemental reimbursement to hospitals to support hospitals using these products. Companies that do not yet have a DCB to offer may also attempt to move into the DCB market to tap on the growth potential of this large market.

With two DBCs by other companies approved by the FDA and a third one in the regulatory process, the Group is optimistic that the highly differentiated Chocolate Touch™ may be the fourth DCB to be approved. Chocolate Touch™ is expected to receive regulatory approval in Europe later this year and the initial clinical trial for Chocolate Touch™ (ENDURE study) is on track to release six months follow up data this fall. By some estimates, the DCB market in the US may be worth US$100 million in 2015 and $600 million in 2018(2)(3).

Chocolate Touch™ is based on the unique Chocolate® angioplasty balloon platform. By reducing acute trauma, Chocolate® has been able to minimize flow-limiting dissections and thus reduce the need for unplanned stenting in the peripheral arteries as compared to conventional balloons(4). Its Chocolate® PTA Balloon Catheter, was the first medical interventional product from Singapore to receive the US FDA clearance. The Chocolate® platform is also used to treat patients' coronary arteries.

With the addition of the proven anti-proliferative drug paclitaxel, Chocolate Touch™ balloons offer the potential to achieve improved acute outcomes that will hold up over time. This additional long-term effect is due to the paclitaxel drug's ability to reduce the body's natural response to vascular intervention, which may otherwise lead to the need for repeat interventions.

(1) Mike Matson, Needham & Company, LLC. Analyst report on C.R. Bard, Inc., 30 January 2015.
(2) StarTribune. "Boston Scientific jumps into the market with a drug-eluting balloon", 10 February 2015.
(3) FierceMedicalDevices. "Medtronic readies for 2015 drug-eluting balloon FDA approval", 11 June, 2014.
(4) Dr. Tony Das, et al. "Chocolate® BAR: Chocolate® PTA in a broad range of patients with PAD, a prospective post-marketing study", LINC 2014

~~ End ~~

ABOUT QT VASCULAR LTD.(SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC ("**TriReme Medical**"), based in Pleasanton, California. TriReme Medical's range of percutaneous transluminal angioplasty ("**PTA"**) and percutaneous transluminal coronary angioplasty ("**PTCA**") products include (i) Chocolate® PTA Balloon Catheter, (ii) Chocolate® PTCA Balloon Catheter, (iii) GliderXtreme™ PTA Balloon Catheter, (iv) GliderfleX® PTA Balloon Catheter and (v) Glider™ PTCA Balloon Catheter, all of which have the CE Mark that allows them to be sold in Europe, and FDA clearance to be sold in the United States. Additionally, the GliderXtreme™ PTA Balloon Catheter has the regulatory clearance in China and Japan, while the Glider™ PTCA Balloon Catheter has the regulatory clearance in Japan. These products are sold through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Johnson & Johnson), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

The Group is also applying for CE marking approval with respect to the Chocolate® Touch, its advanced drug-coated peripheral balloon.

In October 2014, the Group acquired a novel technology platform called Java, and all its associated intellectual property. The Group believes the Java technology is a strong fit with QT Vascular's core expertise in minimally invasive angioplasty.

For more information, please visit the company website at www.qtvascular.com

---

Issued on behalf of **QT VASCULAR LTD.** by:

WATERBROOKS CONSULTANTS PTE LTD
Tel: +65 6100 2228

For media and analysts, please contact:

Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg
Ms Angeline Cheong	(M): +65 9666 0977	angeline@waterbrooks.com.sg

---

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

QT Vascular Ltd. (the "Company") was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.